Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.

G

Guangdong Provincial People's Hospital (Guangdong Provincial Academy of Medical Sciences)

Status

Enrolling

Conditions

Chemotherapy
Immunotherapy
Esophageal Squamous Cell Carcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT06125262
RICE-Circulation

Details and patient eligibility

About

Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.

Full description

Studies have already demonstrated the feasibility of prognostic role of protein biomarkers change during the treatment trajectory of patients in several carcinoma,However, no study focused on the value of trajectory analysis of blood cells counts of Immunochemotherapy in patients with advanced esophageal cancer. The investigators plan to analyze the dynamic change of blood cells counts longitudinally from preoperation to long term follow-up in advanced esophageal cancer and predict the efficacy and safety of immunochemotherapy.

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pathologically confirmed esophageal squamous cell carcinoma
  • Potentially resectable esophageal squamous cell carcinoma at first diagnosis (cT1-4a N1-2 M0, cT3-T4a N0M0)
  • Treatment-naive
  • Expected life span > 6 months
  • Aged 18 - 75 years old
  • Adequate organ functions
  • Performance Status (PS) 0-2
  • Participants are fully informed about the whole study and are willing to sign the informed consent

Exclusion criteria

  • Previous history of thoracic surgery or radiation
  • Cervical or multi-origin esophageal cancer
  • Known or suspected experimental drug allergy
  • Pregnant or lactating women
  • Esophagomediastinal fistula
  • Peripheral neuropathy
  • Previous cancer history other than esophageal cancer
  • Severe organ function deterioration that can not tolerate neoadjuvant therapy
  • Previous autoimmune diseases
  • diabetic history > 10 years
  • interstitial pulmonary disease, non-infectious pulmonitis
  • Active type B hepatitis
  • Any other conditions that may affect patients' safety and compliance

Trial contacts and locations

1

Loading...

Central trial contact

guibin Qiao, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems